Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Spotfire's (Somerville, MA) Clinical Trial Analysis software is built on its DXP enterprise analytics platform for pharmaceutical companies and can be used by physicians, scientists, analysts, and nontechnical staff to discover data relationships related to drug safety and efficacy. This allows companies to address drug design and discovery earlier in the process.
Spotfire Clinical Trial Analysis provides querying capabilities of clinical and molecular data using graphs and charts. It analyzes data from various sources to identify trends, outliers, and exceptions; offers visual representations (charts, plots, graphs) of adverse event data, lab safety, demographics, and concomitant medications; allows for ad hoc data query; finds correlations between gene or protein expressions and safety profiles; and adapts to new technologies and methodologies.
Spotfire, (617) 702-1600, www.spotfire.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.